MedTrace Logo

Noninvasive vs. Invasive Lung Evaluation

NCT03615443 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 306

Last updated 2021-05-03

No results posted yet for this study

Summary

Tumor derived cell free DNA (cfDNA) is increasingly used in the clinic to obtain genotype information about lung cancer, but its concordance with concurrent tumor-derived sequenced data is not known. The purpose of the trial is to determine the non-inferiority of cfDNA-based vs. tumor tissue-based genotyping as it pertains to the detection of National Comprehensive Cancer Network (NCCN)-recommended biomarkers in first line, treatment naive, non-squamous Non-Small Cell Lung Cancer (NSCLC).

Conditions

Interventions

DIAGNOSTIC_TEST

Guardant360

Guardant360 is a comprehensive, non-invasive tumor sequencing test.

Sponsors & Collaborators

  • Guardant Health, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-12
Primary Completion
2020-11-23
Completion
2020-11-23

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03615443 on ClinicalTrials.gov